文献速递浆细胞疾病

高危细胞遗传学对复发/难治性多发性骨髓瘤患者治疗效果和结局的影响:随机对照试验的系统综述与Meta分析

The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Leukemia · 2025-07-02

该系统综述与Meta分析检索PubMed数据库(截至2024年8月20日),纳入28项报告标准危与高危亚组结局的复发/难治性多发性骨髓瘤随机对照试验,其中23项报告无进展生存期、8项报告总生存期。总体分析显示高危细胞遗传学与标准危相比在无进展生存期和总生存期上均未关联治疗效果受损。在9个治疗亚组中,接受抗BCMA治疗的高危患者无进展生存事件风险似乎较该人群总体治疗效应低18%,但结果不显著。

要点

  • 复发/难治性多发性骨髓瘤中高危细胞遗传学与标准危相比,无进展生存期和总生存期均无显著差异。
  • 9个治疗亚组中抗BCMA治疗高危患者无进展生存事件风险似乎低18%,但结果不显著。
  • 亚组分析中del(17p)似乎对治疗效果影响最大,但结果未达统计学显著。

核心结论

  • 在复发/难治性多发性骨髓瘤研究中,入组时存在高危细胞遗传学并未改变治疗效果。
  • 需要新的工具来改善骨髓瘤复发时的风险分层。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed数据库(检索截止2024年8月20日),纳入报告标准危与高危患者亚组结局的抗骨髓瘤治疗随机对照试验,共28项研究。
  • 28项研究中23项报告无进展生存期结局、8项报告总生存期结局。

主要发现

  • 总体分析显示,高危细胞遗传学与标准危相比,在无进展生存期和总生存期上均未关联治疗效果受损。
  • 9个治疗亚组中,接受抗BCMA治疗的高危患者无进展生存事件风险似乎较该人群总体治疗效应低18%,但结果不显著。
  • 亚组分析中,del(17p)似乎对治疗效果影响最大,但结果未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The cytogenetic abnormalities translocations t(4;14) and t(14;16) and the deletion of chromosome 17p in newly-diagnosed multiple myeloma are associated with poor disease prognosis and are traditionally deemed as "high-risk". However, in the setting of relapsed/refractory multiple myeloma (RRMM) their effect is less characterized. A systematic search was conducted in the PubMed database (end-of-search: 20 August 2024) for randomized controlled trials on anti-myeloma therapies for RRMM that reported outcomes for standard-risk and high-risk patient subgroups. A total of 28 studies were included; 23 reported progression-free survival (PFS) and 8 overall survival (OS) outcomes. Per overall analysis, high-risk cytogenetics were not associated with impaired treatment efficacy compared to standard-risk in terms of both PFS and OS. Among 9 treatment subgroups, high-risk patients on anti-BCMA therapies seemed to exhibit a 18% lower risk of a PFS event compared to the overall treatment effect for this population, but results were not significant. In the subgroup analyses, deletion 17p seemed to have the biggest impact on treatment efficacy, but results were not statistically significant. Overall, the presence of high-risk cytogenetics at study entry in RRMM did not alter treatment efficacy. Novel tools are needed to improve risk stratification at myeloma relapse.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, et al. The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Leukemia. 2025. PMID: 40603652. doi:10.1038/s41375-025-02677-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。